Bristol-Myers Squibb's (BMY) Neutral Rating Reiterated at The Goldman Sachs Group

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its "neutral" rating reissued by investment analysts at The Goldman Sachs Group in a research note issued on Tuesday, Marketbeat.com reports. They currently have a $55.00 target price on the biopharmaceutical company's stock, down from their prior target price of $67.00. The Goldman Sachs Group's price target points to a potential upside of 8.53% from the company's current price.

Several other analysts have also weighed in on BMY. Truist Financial raised their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Cantor Fitzgerald increased their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Finally, Bank of America reissued a "neutral" rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $57.67.

Remove Ads

Bristol-Myers Squibb Price Performance

NYSE BMY traded up $0.22 during trading on Tuesday, reaching $50.68. 13,408,290 shares of the company traded hands, compared to its average volume of 12,924,946. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a market cap of $103.11 billion, a price-to-earnings ratio of -11.46, a P/E/G ratio of 2.07 and a beta of 0.41. The stock's 50 day moving average price is $57.71 and its two-hundred day moving average price is $56.73. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Institutional Trading of Bristol-Myers Squibb

A number of large investors have recently made changes to their positions in the company. United Bank increased its stake in Bristol-Myers Squibb by 2.7% during the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 456 shares in the last quarter. Morse Asset Management Inc raised its holdings in shares of Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock worth $517,000 after acquiring an additional 2,000 shares during the period. MML Investors Services LLC lifted its position in Bristol-Myers Squibb by 1.5% in the 3rd quarter. MML Investors Services LLC now owns 313,688 shares of the biopharmaceutical company's stock valued at $16,230,000 after acquiring an additional 4,554 shares in the last quarter. Geller Advisors LLC boosted its stake in Bristol-Myers Squibb by 19.1% in the 3rd quarter. Geller Advisors LLC now owns 5,976 shares of the biopharmaceutical company's stock worth $309,000 after purchasing an additional 958 shares during the period. Finally, LRI Investments LLC raised its stake in shares of Bristol-Myers Squibb by 58.6% in the 3rd quarter. LRI Investments LLC now owns 4,190 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 1,548 shares during the period. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.